AGC Biologics, a leading global biopharmaceutical contract development and manufacturing organization (CDMO), announced that its partnership with Horizon Therapeutics plc is expanding to produce the treatment Thyroid Eye Disease (TED) Clinic, TEPEZZA, at AGC's new facility in Boulder, CO. The state-of-the-art facility includes two 20,000L stainless steel mammalian bioreactors that AGC offers to customers in need of high volume commercial production.

"We have partnered with AGC on TEPEZZA production for over three years and have seen excellent collaboration between our technical teams, which has resulted in rapid process transfer and efficient launch," said Michael DesJardin, Executive Vice President, technical operations and corporate quality, Horizon. "AGC has a deep understanding of TEPEZZA and we look forward to expanding our partnership."

AGC and Horizon began partnering in 2017 and there are ongoing projects at AGC's facilities in Copenhagen and Seattle. Horizon will now be AGC's first customer to have a product manufactured at the new site in Boulder. The facility is well equipped for the production of TEPEZZA. Following approval, the facility is expected to produce the majority of TEPEZZA's supply.

"We are excited to expand our strategic partnership with Horizon by leveraging large-scale stainless steel capacity at our new facility in Boulder, " said Mark Womack, Business Director for AGC Biologics. "Our globally aligned network is equipped and ready to continue supplying TEPEZZA to the market."